Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease.

Marianne LuinstraWijnand RutgersTeus van LaarFloris GrasmeijerAnja BegemanValmira IsufiLuc SteenhuisPaul HagedoornAnne de BoerHenderik W Frijlink

Published in: Therapeutic advances in chronic disease (2019)

Inhaled levodopa is well tolerated, absorbed faster than oral levodopa, and can be robustly administered over a range of inhalation flow profiles. It therefore appears suitable for the treatment of off periods in Parkinson's disease.

Keyphrases

parkinson disease
deep brain stimulation
cystic fibrosis
open label
randomized controlled trial
clinical trial
combination therapy
placebo controlled